Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation

References

• Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91–97.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–1883.
   PubMed Web of Science ®Google Scholar
• Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–1629.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F. Have drug combinations supplanted stem cell transplantation in myeloma? Blood. 2012;120(24):4692–4698.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2014 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2014;89(10):998–1009.
   Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Teruel A, et al. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia. 2017;31(9):1922–1927.
   PubMed Web of Science ®Google Scholar
• Stoppa AM, Coso D, Fouquet G, et al. Consolidation and maintenance in de novo first-line multiple myeloma with modern agents. Int J Hematol Oncol. 2015;4(1):9–22.
   Google Scholar
• de Tute RM, Cairns D, Rawstron A, et al. Minimal residual disease in the maintenance setting in myeloma: prognostic significance and impact of lenalidomide. Blood. 2017;130(Supplement 1): 904–904.
   Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35.
   PubMed Web of Science ®Google Scholar
• Biran N, Ely S, Chari A. Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques. Curr Hematol Malig Rep. 2014;9(4):368–378.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang F, Shen Y, et al. Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review. J Natl Cancer Inst. 2016;108(3):djv342.
   PubMedGoogle Scholar
• Abonour R, Wagner L, Durie BG, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the connect® MM registry. Ann Hematol. 2018;97(12):2425–2436.
   PubMed Web of Science ®Google Scholar
• Jackson G, Dutton R, Zamagni E, et al. Lenalidomide maintenance therapy post-autologous stem cell transplant: a healthcare cost-impact analysis in Europe. Blood. 2017;130(Supplement 1): 3405–3405.
   Google Scholar
• Sengsayadeth S, Malard F, Savani B, et al. Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J. 2017;7(3):e545–e545.
   PubMedGoogle Scholar
• Maiolino A, Hungria VT, Garnica M, et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression‐free survival in multiple myeloma. Am J Hematol. 2012;87(10):948–952.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. Blood. 2012;119(1):7–15.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the national cancer institute of canada clinical trials group myeloma 10 trial. Blood. 2013;121(9):1517–1523.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, van der Holt B, Minnema MC, et al. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Hematol. 2018;5(10):e479–e492.
   PubMed Web of Science ®Google Scholar
• Kim S-A, Yoon -S-S, Koh Y, et al. Thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed Korean multiple myeloma patients: a prospective multi-center study in Asia. Blood. 2017;130(Supplement 1): 1814–1814.
   Google Scholar
• Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010;115(6):1113–1120.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial. Blood. 2013;122(21):406.
   Web of Science ®Google Scholar
• Cherniawsky H, Sandhu I, Chu MP, et al. The survival impact of lenalidomide maintenance chemotherapy in multiple myeloma patients treated with autologous stem cell transplant and bortezomib-based induction: an analysis of real world data. Blood. 2017;130(Supplement 1): 3132–3132.
   Google Scholar
• Cote J, Phillips M, Atenafu EG, et al. Pattern of first relapse in multiple myeloma (MM) patients (Pts) after a cybord induction regimen and autologous stem cell transplantation (ASCT): impact of maintenance therapy in the real-world setting. Blood. 2016;128(22):2137.
   Web of Science ®Google Scholar
• Fonseca R, Parikh K, Ung B, et al. Real-world outcomes for maintenance treatment sequencing after receiving lenalidomide, bortezomib, and dexamethasone induction in patients with newly diagnosed multiple myeloma (NDMM) followed by autologous stem cell transplant (ASCT). Blood. 2017;130(Supplement 1): 3463–3463.
   PubMedGoogle Scholar
• Goldschmidt H, Mai EK, Dürig J, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020;34:1–13.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Jung S-H, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4(9):e431–e442.
   PubMed Web of Science ®Google Scholar
• Jackson GH, Davies F, Pawlyn C, et al. Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: results of the myeloma XI study. J Clin Oncol. 2017;35(15_suppl): 8009–8009. DOI:10.1200/JCO.2017.35.15_suppl.8009.
   Google Scholar
• Jagannath S, Abonour R, Durie BG, et al. Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry. J Clin Oncol. 2017;35(15_suppl): 8040–8040. DOI:10.1200/JCO.2017.35.15_suppl.8040.
   Google Scholar
• McCarthy P, Holstein S, Jung S-H, et al. Overall Survival (OS) and progression-free survival (PFS) adjusted for treatment crossover in the CALGB/ECOG 100104 (Alliance) study of lenalidomide (LEN) versus placebo (PBO) maintenance after stem cell transplant (SCT) for patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17(1):e135.
   Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–1781.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905.
   PubMed Web of Science ®Google Scholar
• Yang C, Jiang H, Masih-Khan E, et al. Tolerability and efficacy of post transplant lenalidomide maintenance therapy in multiple myeloma: a real world single centre experience. Blood. 2017;130(Supplement 1): 3462–3462.
   Google Scholar
• Luoma S, Anttila P, Saily M, et al. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the finnish myeloma group. Ann Hematol. 2019 Dec;98(12):2781–2792.
   PubMed Web of Science ®Google Scholar
• Mina R, Petrucci MT, Corradini P, et al. Treatment intensification with autologous stem cell transplantation and lenalidomide maintenance improves survival outcomes of patients with newly diagnosed multiple myeloma in complete response. Clin Lymphoma Myeloma Leuk. 2018;18(8):533–540.
   PubMed Web of Science ®Google Scholar
• Sborov DW, Benson DM, Williams N, et al. Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. Br J Haematol. 2015;171(1):74–83.
   PubMed Web of Science ®Google Scholar
• Thomas SK, Shah JJ, Morphey AN, et al. Updated results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM). Blood. 2018;132(Supplement 1): 1982–1982. DOI:10.1182/blood-2018-99-116464.
   PubMedGoogle Scholar
• Sharma N, Chen DT, Zhao Q, et al. Lenalidomide and vorinostat maintenance after autologous transplantation in multiple myeloma: long-term follow-up. Biol Blood Marrow Transplant. 2020;26(1):44–49.
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Lokhorst H, Mai E, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018;32(2):383–390.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clini Oncol. 2012;30(24):2946–2955.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Salwender H-J, Van Der Holt B, et al. Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: long-term follow-up of the HOVON-65/GMMG-HD4 trial. Blood. 2015;126(23): 27–27.
   Web of Science ®Google Scholar
• Merz M, Jauch A, Hielscher T, et al. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv. 2018;2(1):1–9.
   PubMed Web of Science ®Google Scholar
• Solovev MV, Mendeleeva LP, Pokrovskaya OS, et al. Maintenance therapy after autologous haematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma patients with and without minimal residual disease (MRD). Blood. 2016;128(22):2260.
   Web of Science ®Google Scholar
• Moreau P, Hulin C, Caillot D, et al. Ixazomib-lenalidomide-dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance in patients with newly diagnosed multiple myeloma (NDMM): a phase 2 study from the Intergroupe Francophone Du MyéLome (IFM). Blood. 2016;128(22):674.
   Google Scholar
• Morgan G, Dimopoulos M, Gay F, et al. Maintenance therapy with the oral proteasome inhibitor (PI) ixazomib significantly prolongs progression-free survival (PFS) following autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM): phase 3 tourmaline-MM3 trial. Biol Blood Marrow Transplant. 2019;25(3):S19–S20.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28(3):690–693.
   PubMed Web of Science ®Google Scholar
• Nadiminti K, Strouse C, Vikas P, et al. A single autologous stem cell transplant (ASCT) followed by two years of post-transplant therapy in recently diagnosed elderly multiple myeloma (MM) patients. Safety and response results from the prospective phase II trial (NCT01849783). Blood. 2018;132(Supplement1): 2153–2153.
   Google Scholar
• Gay F, Cerrato C, Rota Scalabrini D, et al. Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 cycles vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation: analysis of the randomized Forte trial in newly diagnosed multiple myeloma (NDMM). Blood. 2018;132(Supplement 1): 121–121.
   Google Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29–38.
   PubMed Web of Science ®Google Scholar
• Lin T, Hampras S, Krey R, et al. Daratumumab plus lenalidomide versus lenalidomide alone as maintenance treatment in patients with newly diagnosed multiple myeloma after frontline transplant: a multicenter, randomized, phase 3 study (AURIGA). Clin Lymphoma Myeloma Leuk. 2019;19(10):e199.
   Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); [ cited 2020 Sep 12]. Available from: https://clinicaltrials.gov/ct2/home
   Google Scholar